Evidence map›Paper›PMID 41635378›Full record

ArticleCureus2026

Efficacy of Plasma Exchange in Secondary Thrombotic Microangiopathy: A Case Report and Literature Review.

Shohei Fukunaga, Naohito Masuda, Yudo Tanno, Takashi Yokoo

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shohei FukunagaNephrology and Hypertension, The Jikei University Katsushika Medical Center, Katsushika-Ku, JPN.
Naohito MasudaNephrology and Hypertension, The Jikei University Katsushika Medical Center, Katsushika-Ku, JPN.
Yudo TannoNephrology and Hypertension, The Jikei University Katsushika Medical Center, Katsushika-Ku, JPN.
Takashi YokooNephrology and Hypertension, The Jikei University School of Medicine, Minato-Ku, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thrombotic microangiopathy (TMA) is a severe syndrome characterized by thrombocytopenia, microangiopathic hemolytic anemia, and organ damage. It includes primary forms such as thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic uremic syndrome, as well as secondary TMA, which can result from conditions such as autoimmune diseases, infections, and malignancies. While plasma exchange (PE) is a well-established treatment for thrombocytopenic purpura, its effectiveness against secondary TMA is debated, primarily because of the varying etiologies and pathomechanisms. There is a lack of comprehensive studies on the effectiveness of PE based on the underlying causes of secondary TMA. Herein, we report a woman in her 60s who was undergoing treatment for systemic lupus erythematosus (SLE). She presented with lower back pain and altered consciousness. The patient was diagnosed with a urinary tract infection and severe thrombocytopenia (1,000/μL). A PLASMIC score of 6 indicated a high likelihood of TTP, prompting the initiation of PE, which improved her platelet count. Her A disintegrin and metalloproteinase with thrombospondin motif 13 activity was 16%, confirming secondary TMA. The efficacy of PE for secondary TMA remains debated, with its effectiveness likely varying depending on the underlying cause. Case reports suggest poor outcomes for TMA caused by malignancies, whereas other causes tend to be associated with more favorable prognoses. However, no study has specifically examined the effectiveness of PE based on the primary underlying condition, highlighting the need for further research.

Indexed as

infectionplasma exchange therapysecondary thrombotic microangiopathysystemic lupus erythematosusthrombotic thrombocytopenic purpura

Identifiers

PMID41635378
PMCPMC12862222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.